Chaoju Eye Care Holdings Limited filed a Next Day Disclosure Return with the Hong Kong Stock Exchange on 14 April 2026, confirming that the company’s issued share capital remained unchanged at 705.18 million ordinary shares as of the same date. No treasury shares were held.

The document highlights a new on-market repurchase carried out on 14 April 2026, when 60,000 shares were bought at prices ranging from HKD 2.79 to HKD 2.89, for a total cash outlay of HKD 168,315. These shares are earmarked for cancellation.

Including earlier transactions on 2 April (10,000 shares at an average HKD 2.72) and 9 April (17,500 shares at an average HKD 2.82), the company has bought back 87,500 shares this month that are pending cancellation.

Under the repurchase mandate approved on 6 June 2025, Chaoju Eye Care is authorised to buy back up to 70.75 million shares. To date, 2.42 million shares—or 0.34 % of the issued share total on the mandate date—have been repurchased. The company is subject to a 30-day moratorium on new share issues or treasury-share sales, lasting through 14 May 2026.

The filing confirms that all repurchase activities complied with Hong Kong listing rules, applicable laws and the terms of the shareholder mandate.